Value of infliximab (Remicade(R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group

Baron, F.; Suciu, S.; Amadori, S.; Muus, P.; Zwierzina, H.; Denzlinger, C.; Delforge, M.; Thyss, A.; Selleslag, D.; Indrak, K.; Ossenkoppele, G.; de Witte, T.

期刊名称Haematologica
作者Baron, F.; Suciu, S.; Amadori, S.; Muus, P.; Zwierzina, H.; Denzlinger, C.; Delforge, M.; Thyss, A.; Selleslag, D.; Indrak, K.; Ossenkoppele, G.; de Witte, T.
卷第97卷
期第4期
印刷ISSN0390-6078
电子ISSN1592-8721
文件大小378.58KB
发表时间2012-04-01
DOI10.3324/haematol.2011.044347
页码529-533

发现好书期刊，享受阅读乐趣

Value of infliximab (Remicade(R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group